These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15712148)

  • 21. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
    Eichhorst BF; Busch R; Obwandner T; Kuhn-Hallek I; Herschbach P; Hallek M;
    J Clin Oncol; 2007 May; 25(13):1722-31. PubMed ID: 17389338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is bone marrow biopsy a prognostic parameter in B-CLL?
    Raphael M; Chastang C; Binet JL
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):377-8. PubMed ID: 3222148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Bone marrow changes in patients with hairy cell leukemia after 2-chlorodeoxyadenosine treatment].
    Urasiński I; Zdziarska B; Krygier-Stojałowska A
    Acta Haematol Pol; 1996; 27(1):49-55. PubMed ID: 8629443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia.
    MacCallum S; Groves M; Brass D; Cunningham J; Sales M; Gelly K; Tauro S
    J Clin Pathol; 2009 May; 62(5):468-70. PubMed ID: 19398596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment.
    Lysak D; Koza V; Steinerova K; Jindra P; Vozobulova V; Schutzova M
    Ann Hematol; 2005 Jul; 84(7):456-61. PubMed ID: 15770494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow biopsy in chronic lymphocytic leukaemia: a study of 208 cases.
    Montserrat E; Rozman C
    Haematologia (Budap); 1983; 16(1-4):73-9. PubMed ID: 6679490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Structural and functional changes of bone marrow stroma in chronic lymphocytic leukemia].
    Shatseva TA; Rugal' VI; Novozhilova AP; Kiseleva MV; Zhiburt EB
    Vopr Onkol; 1999; 45(3):249-53. PubMed ID: 10443225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
    Eichhorst BF; Busch R; Schweighofer C; Wendtner CM; Emmerich B; Hallek M;
    Br J Haematol; 2007 Jan; 136(1):63-72. PubMed ID: 17083342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An unusual case of chronic lymphocytic leukemia.
    Hollander SL
    J Med; 1991; 22(4-5):289-97. PubMed ID: 1787387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choice of endothelial marker is crucial for assessment of bone marrow microvessel density in chronic lymphocytic leukemia.
    Smolej L; Kasparová P
    APMIS; 2008 Dec; 116(12):1058-62. PubMed ID: 19133008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
    Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications.
    Tadmor T; Shvidel L; Aviv A; Ruchlemer R; Bairey O; Yuklea M; Herishanu Y; Braester A; Rahimi-Levene N; Vernea F; Ben-Ezra J; Bejar J; Polliack A;
    Cancer; 2013 May; 119(10):1853-9. PubMed ID: 23423815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation.
    Cheson BD
    Semin Hematol; 1998 Jul; 35(3 Suppl 3):14-21. PubMed ID: 9685175
    [No Abstract]   [Full Text] [Related]  

  • 35. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
    Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
    Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
    J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia.
    Rossini MS; de Souza EM; Cintra ML; Pagnano KB; Chiari AC; Lorand-Metze I
    J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):538-42. PubMed ID: 15324388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chronic lymphatic leukemia. Peroral cladribine as primary treatment].
    Gjedde SB; Juliusson G; Hansen MM
    Ugeskr Laeger; 1996 Nov; 158(45):6432-4. PubMed ID: 8992677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
    J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
    Maddocks-Christianson K; Slager SL; Zent CS; Reinalda M; Call TG; Habermann TM; Bowen DA; Hoyer JD; Schwager S; Jelinek DF; Kay NE; Shanafelt TD
    Br J Haematol; 2007 Nov; 139(3):398-404. PubMed ID: 17910629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.